Tumor mutational load, CD8(+) T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients

OBJECTIVES: A minority of NSCLC patients benefit from anti-PD1 immune checkpoint inhibitors. A rational combination of biomarkers is needed. The objective was to determine the predictive value of tumor mutational load (TML), CD8(+) T cell infiltration, HLA class-I and PD-L1 expression in the tumor....

Descripción completa

Detalles Bibliográficos
Autores principales: Hurkmans, Daan P., Kuipers, Merian E., Smit, Jasper, van Marion, Ronald, Mathijssen, Ron H. J., Postmus, Piet E., Hiemstra, Pieter S., Aerts, Joachim G. J. V., von der Thüsen, Jan H., van der Burg, Sjoerd H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183487/
https://www.ncbi.nlm.nih.gov/pubmed/32047958
http://dx.doi.org/10.1007/s00262-020-02506-x

Ejemplares similares

Ejemplares similares